Bend Research, Inc.

Pfizer Corporation

Zalicus Pharmaceuticals, Ltd.

Bend Reseach, Inc.

Marshall David Crew

Dwayne Thomas Friesen

Ravi Mysore Shanker

Daniel Tod Smithey

Leah Elizabeth Appel

James William West

Roderick Jack Ray

James A S Nightingale

Roger B Ruggeri

William John Curatolo

Corey Bloom

Warren Kenyon Miller

Douglas Alan Lorenz

David Keith Lyon

Scott B McCray

Michael Jon Gumkowski

Walter Christian Babcock

Scott Max Herbig

Julian B Lo

Michael Mark Morgen

Rodney James Ketner

Bruno Caspar Hancock

Joshua R Shockey

William Brett Caldwell

Jeff T Gautschi

Mahesh V Padval

David D Newbold

Avinash G Thombre

James Blair West

Ravi Mysore Shankar

Timothy A Hagen

Chris Macri

Stephen J Schadtle

John E Byers

Corey Jay Bloom

Leah Elisabeth Appel

Roger Benjamin Ruggeri

James Alan Schriver Nightingale

Ravi Moysore Shanker

A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.

Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer

High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility.

Immediate release dosage forms containing solid drug dispersions

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.

Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer

A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.

Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer

The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.

Solid dispersion formulations and methods of use thereof

A solid composition of a low-solubility drug and a concentration-enhancing polymer has a portion of the drug in a semi-ordered state.

Pharmaceutical compositions of semi-ordered drugs and polymers

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed.

Pharmaceutical compositions of drugs and neutralized acidic polymers

A process for forming drug multiparticulates having improved drug crystallinity is disclosed, comprising modifying a conventional melt-congeal process by adding a volatile cospecies either to the molten mixture or to the process atmosphere, or to both.

Method of making pharmaceutical multiparticulates

A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.

Multiparticulate crystalline drug compositions having controlled release profiles

A process is described for producing drug-containing multiparticulates with improved stability, characterized by an improvement in one or more of chemical stability, physical stability, or dissolution stability.

Multiparticulate compositions with improved stability

Growing community of inventors

Bend, OR, United States of America

Marshall David Crew